HOME >> MEDICINE >> NEWS
Anti-Clotting Drug May Cause Potentially Fatal Platelet Disorder

CHICAGO --- Ticlopidine, a drug that acts like aspirin and is widely used to prevent stroke as well as blood clot formation following placement of cardiac stents, can cause a rare but potentially deadly disease. The disorder, thrombotic thrombocytopenic purpura (TTP), generally develops within four weeks of starting ticlopidine therapy.

Symptoms of TTP include mass destruction of blood platelets, anemia, neurologic changes, progressive renal failure and fever. The cause is unknown, but in very uncommon cases, drugs other than ticlopidine, including penicillin, some anti-cancer drugs and oral contraceptives, have been associated with the syndrome.

TTP has been considered an extremely rare disorder -- less than four cases per million persons, with an overall death rate that was originally reported at 90 percent. With improvements in diagnosis and treatment, the mortality rate is now in the range of 10 to 20 percent.

However, a Northwestern University Medical School study has found that TTP as a side effect of ticlopidine occurs far more frequently than in the general population, and the mortality rate may be as high as 33 percent.

The Northwestern study also found that mortality was almost 50 percent for those older than 60, but only 16 percent in those younger than 60. One reason for the high death rate among patients who take ticlopidine for prevention of stroke is that the neurologic symptoms of TTP are similar to those of stroke.

In the past year, ticlopidine use has been expanded to include persons who undergo angioplasty and have a cardiac stent implanted during the procedure. Fifteen cases of ticlopidine-associated TTP were found in these patients, almost always presenting with acute onset of stroke-like symptoms, which facilitated the recognition of this life-threatening complication. Nonetheless, about one fifth of patients who received ticlopidine following cardiac stents died within fo
'"/>

Contact: Elizabeth Crown
e-crown@nwu.edu
312-503-8928
Northwestern University
1-Apr-1998


Page: 1 2 3

Related medicine news :

1. Cause for massively enlarged spleens in tropical countries
2. Causes of menstrual migraine explored
3. Major Causes Of Early Childhood Death From Injury Identified
4. New Model Shows How To Eradicate Worlds Leading Infectious Cause Of Blindness
5. Causes, Prevention Of Dwarfism Are Goals Of International Skeletal Dysplasia Registry At Cedars-Sinai Medical Center
6. Motion Blindness, Not Just Poor Memory, Causes Alzheimers Patients To Lose Their Way
7. A Trip To The Dentist Could Cause Symptoms In Asthmatic Kids
8. Drug Treatments For Asthma May Cause Erosive Tooth Damage
9. Controlling Collagen Levels May Be Key To Fighting Organ Failure Caused By High Blood Pressure
10. Drug Prevents Hearing Loss Caused By Brain Tumor Therapy
11. Anti-Migraine Drugs Might Cause More Pain Than Relief For Those With Heart Disease

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Anti Clotting Drug May Cause Potentially Fatal Platelet Disorder

(Date:5/18/2013)... 2013 The “World Healthcare IT Market: ... the major market drivers, restraints, and opportunities in North ... Browse , 89 market data ... on "Healthcare IT Market" , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html ... reports. , The global healthcare IT market is expected ...
(Date:5/18/2013)... May 18, 2013 During Better Hearing ... should consider the legal protections they have, including the ... arise with their child’s treatment or hearing aid device, ... 1927, the American Speech-Language-Hearing Association has used the month ... to promote treatment, such as cochlear implants, which can ...
(Date:5/18/2013)... Adolescents, especially young males, who experiment with synthetic ... landing in emergency rooms across America. Recovery ... with a new treatment program for those addicted to ... the National Institute on Drug Abuse, synthetic marijuana has ... In 2012, 11 percent of high school seniors had ...
(Date:5/18/2013)... May 18, 2013 The American ... John A. Kitzhaber, M.D., (D) to sign a bill ... prohibiting minors under the age of 18 from tanning ... the third state in the nation to enact an ... similar indoor tanning bans for minors. Nationwide, 34 states ...
(Date:5/18/2013)... The topics that will be covered in the 1-day ... meetings, scrum artifacts, and scrum simulation (optional). One can earn ... These trainings are suitable for business analysts, project managers, developers, ... will be a part of the Scrum team, people outside ... and Scrum, but are unsure of what it is. ...
Breaking Medicine News(10 mins):Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 2Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 3Health News:Spice Addiction Treatment and Synthetic Marijuana Drug Rehab Announced by Recovery Associates 2Health News:ASDSA Urges Oregon Governor to Sign Under-18 Indoor Tanning Restrictions 2Health News:Affordable Scrum Trainings In Irvine by Conscires Agile Practices 2Health News:Affordable Scrum Trainings In Irvine by Conscires Agile Practices 3
(Date:5/17/2013)... Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ( http://www.oramed.com ... today that the United States Food and Drug Administration ... for ORMD-0801, its oral insulin capsule. "We ... proceed," stated Nadav Kidron , CEO ... for Oramed and we look forward to continuing to ...
(Date:5/16/2013)... ZURICH , May 17, 2013 ... Technology and Research (A*STAR) and Switzerland,s ... has been dosed in a Phase 1 clinical trial with ... Qbeta virus-like particle (VLP) technology. In this first Phase 1 ... candidate and its potential to protect against H1N1 influenza infection ...
(Date:5/16/2013)... , May 16, 2013  Nektar Therapeutics, (Nasdaq: ... W. Robin , is scheduled to present at the ... York at the Sheraton New York Hotel on ... The presentation will be accessible via a Webcast through ... of the Nektar website: http://www.nektar.com . This Webcast will ...
Breaking Medicine Technology:Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City 2
Cached News: